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Minor histocompatibility antigens are the main targets of donor-derived T-cells after
allogeneic stem cell transplantation. Identification of these antigens and understanding
their biology are a key requisite for more insight into how graft vs. leukemia effect and graft
vs. host disease could be separated. We here identified four new HLA class II-restricted
minor histocompatibility antigens using whole genome association scanning. For one of
the new antigens, i.e., LB-PIP4K2A-1S, we measured strong T-cell recognition of the
donor variant PIP4K2A-1N when pulsed as exogenous peptide, while the endogenously
expressed variant in donor EBV-B cells was not recognized. We showed that lack of T-
cell recognition was caused by intracellular cleavage by a protease named asparagine
endopeptidase (AEP). Furthermore, microarray gene expression analysis showed that
PIP4K2A and AEP are both ubiquitously expressed in a wide variety of healthy tissues,
but that expression levels of AEP were lower in primary acute myeloid leukemia (AML).
In line with that, we confirmed low activity of AEP in AML cells and demonstrated that
HLA-DRB1∗03:01 positive primary AML expressing LB-PIP4K2A-1S or its donor variant
PIP4K2A-1N were both recognized by specific T-cells. In conclusion, LB-PIP4K2A-
1S not only represents a novel minor histocompatibility antigen but also provides
evidence that donor T-cells after allogeneic stem cell transplantation can target the
autologous allelic variant as leukemia-associated antigen. Furthermore, it demonstrates
that endopeptidases can play a role in cell type-specific intracellular processing and
presentation of HLA class II-restricted antigens, which may be explored in future
immunotherapy of AML.
Keywords: minor histocompatibility antigens, CD4 T-cells, HLA class II, allogeneic stem cell transplantation, graft
vs. leukemia effect
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INTRODUCTION
HLA-matched allogeneic stem cell transplantation (alloSCT) is
a routinely applied treatment option for many hematological
malignancies (1). Donor-derived T-lymphocytes can thereby
recognize residual malignant cells of the patient, leading to the
beneficial graft vs. leukemia (GvL) effect (2). These T-cells are
directed against minor histocompatibility antigens, which are
polymorphic peptides differentially presented on patient and
donor cells that are able to elicit CD8+ or CD4+ donor T-cells
in the context of self-HLA (3). A variety of HLA-class I- and II-
restricted minor histocompatibility antigens have been identified
by different techniques (4–11), and for several of these antigens,
the appearance of specific CD8+ T-cells was closely followed by
complete remissions of the malignancies (12–15), indicating the
clinical relevance of these T-cells.
Different mechanisms have been shown to create HLA class
I-restricted minor histocompatibility antigens. Most antigens are
encoded by “missense” single-nucleotide polymorphisms (SNPs)
in coding gene regions that directly lead to an amino acid
change in the protein. Antigens can also be created by SNPs in
coding gene regions that are synonymous in the normal reading
frame, but missense in an alternative reading frame. In addition,
antigens can be derived from proteins that are translated in an
alternative reading frame as a result of small indels, such as
for LRH-1 (13) or due to the presence of a non-polymorphic
alternative start codon as shown for LB-ECGF-1H (14) and LB-
ADIR-1F (15). Even SNPs in non-coding gene regions can create
polymorphic antigens as a result of alternative mRNA splicing,
as reported for PANE1 (16), ACC-6 (17), ITGB2 (18), and TTK
(19). Finally, antigens can be encoded by polymorphic genes that
are present in the patient, but homozygously deleted in the donor
as shown for UGT2B17 (20).
Besides a direct difference in interaction of the presented
peptide with the T-cell receptor (TCR), also differential
processing of patient and donor variants can determine the
immunogenicity of a polymorphism. Intracellular processing has
been described to preclude surface presentation of the donor
variant of HA-3 (21), HA-8 (22), LB-NUP133-1R (23), and
possibly HA-2 (24). These donor variants induce strong T-cell
activation after exogenous peptide loading, but fail to activate
specific T-cells when endogenously expressed, demonstrating
that insufficient processing of the donor variant into the HLA
class I pathway is the underlying reason for lack of T-cell
recognition. Finally, it has been shown for HA-1 that impaired
binding affinity of the donor variant to HLA-A∗02:01 leads
to an increased dissociation and therefore insufficient surface
presentation (25).
Here, we present the identification of four new HLA class II-
restricted minor histocompatibility antigens by whole genome
association scanning (WGAS). For three of these antigens,
donor variant peptides were not recognized by specific T-
cells when pulsed exogenously on donor EBV-LCL, suggesting
that immunogenicity of the patient antigen is attributed to
induction of T-cells expressing TCR that are able to discriminate
between polymorphic residues. For the remaining antigen, i.e.,
LB-PIP4K2A-1S, we demonstrate that immunogenicity is at
least partially mediated by intracellular cleavage of the donor
variant by a protease named asparagine endopeptidase (AEP),
thereby precluding its surface presentation. Interestingly, AEP
is expressed at low levels in primary acute myeloid leukemia
(AML), which hinders differential cleavage of polymorphic
peptides and leads to strong T-cell recognition of both patient-
and donor-type antigens when presented by HLA class II.
MATERIALS AND METHODS
Hematopoietic Cell Isolation
Peripheral blood was obtained from healthy individuals and
patients with leukemia after approval by the Leiden University
Medical Center Institutional Review Board and informed consent
according to the Declaration of Helsinki. Peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll-Isopaque
separation and cryopreserved. CD34+ hematopoietic stem cells
were isolated from stem cell grafts and CD33+ AML blasts from
peripheral blood or bone marrow by flow cytometric cell sorting.
Cell Culture
MJS, SD1 (26), and EBV-transformed B-cell lines (EBV-
LCL) were cultured in IMDM (Lonza BioWhittaker)
supplemented with 10% fetal calf serum (FCS) (Cambrex),
1% penicillin/streptomycin (Lonza), and 1.5% L-glutamine
(Lonza). T-cell clones were cultured in IMDM supplemented
with 5% human AB serum (Anprotec), 5% FCS, and 100 IU/ml
interleukin-2 (IL-2) (Chiron), and restimulated every 10–20
days with irradiated (50 gray) allogeneic PBMCs and 0.8µg/ml
phytohemagglutinin (PHA) (Oxoid).
Whole Genome Association Scanning
WGAS was performed as previously described (27). Briefly, a
panel of 80 EBV-LCL was genotyped for 1.1 million SNPs using
microarrays. T-cell recognition of the panel was measured after
retroviral transduction with the HLA-DRB1∗03:01 restriction
molecule, and recognition patterns were compared with SNP
genotype data. The level of matching between the patterns
of T-cell recognition and SNP genotypes was calculated by
Fisher’s exact test using PLINK WGA analysis software (28).
For WGAS, test results needed to be categorized in two distinct
groups. Therefore, EBV-LCL were divided into positive and
negative groups based on the level of IFN-γ production. WGAS
was performed by combining T-cell recognition with SNP
genotyping data.
Sequencing of PIP4K2A Genotype
Genomic DNA of patient- and donor-derived EBV-LCL, MJS,
primary AML, and primary healthy CD34+ hematopoietic stem
cells was isolated by using QIAampDNABloodmini kit (Qiagen)
mini columns. DNA concentrations have been measured using
a NanoDrop Microvolume spectrophotometer (Thermo Fisher).
PCR amplification (initial denaturation 2min 30 s; 94◦C; 40
cycles: denaturation 45 s; 95◦C, annealing 45 s; 60◦C, elongation
1min 30 s; 72◦C; final elongation 10min, 72◦C) was performed
using 100 ng of genomic DNA with the following primers: 5′-
GCC AAA GAA CTG CCA ACT CT-3′ (forward primer) and
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5′-GGC CTC TCC ACT GAC TGT TC-3′ (reverse primer). PCR
products were purified using the QIAquick PCR purification kit
(Qiagen). Sanger sequencing was performed using 25 pmol of the
forward and reverse primer, respectively, and 200 ng of purified
PCR product. Sequence reaction was performed by Eurofins
Genomics (Luxembourg).
Flow Cytometry
For isolation of retrovirally transduced cells carrying the
marker gene CD2, APC-labeled anti-murine CD2 (clone RM2-
5; Biolegend) was used. Healthy hematopoietic stem cells
were isolated based on expression of CD34 using PE-labeled
anti-CD34 (8G12; BD) and acute myeloid leukemic cells
were isolated based on expression of CD33 using BV421-
labeled anti-CD33 (WM53; BD). Cells were washed twice with
phosphate-buffered saline containing 2% FCS and incubated
with fluorochrome-conjugatedmonoclonal antibodies for 30min
at room temperature. Data acquisition was performed on a
fluorescence-activated cell sorter Canto II and a fluorescence-
activated cell sorter BD FACS Aria (BD Biosciences). Forward
scatter/side scatter was used for gating on viable cells. FSC-H/-A
was used for doublet exclusion. Data were analyzed with Kaluza
2.1. (Beckman Coulter).
Retroviral Constructs and Transduction
All experiments involving retroviral vectors were approved by
the government and handled according to biosafety level 2. All
constructs were cloned in MP71 retroviral vectors containing
different marker genes. PIP4K2A was linked to the GFP
marker gene, AEP to murine 1CD2, and HLA-DRB1∗03:01 to
1NGFR. All constructs were verified by sequencing. Retroviral
supernatant was obtained by transfecting wild-type Φnx-
A packaging cells as previously described (29), with the
exception that the X-tremeGENEHPDNA Transfection Reagent
transfection kit (Roche Diagnostics) was used. Non-tissue
culture-treated culture plates were coated (overnight at 4◦C)
with RetroNectin (30µg/ml) Recombinant Human Fibronectin
Fragment (Takara) before harvested retroviral supernatants were
applied and centrifuged at 32◦C for 2 h at 2,000 g. After
centrifugation, cells (1–5 × 105) were directly transferred into
the infectious supernatant and marker gene expression measured
after 3 days by flow cytometry.
Antigen Presentation Assays
Stimulator cells (3 × 104 cells/well or as indicated) were co-
incubated with the CD4+ T-cell clone (5 × 103 cells/well or as
indicated) overnight at 37◦C in 96-well plates in duplicates. For
peptide loading, stimulator cells were incubated with indicated
peptide concentrations for 2 h at 37◦C before T-cell clones were
added. For shutdown of the tet-off system, cells were cultured
in the presence of 50µg/ml doxycycline and washed twice
before co-incubation with the T-cell clone. Cytokine release was
measured after overnight incubation in 100-µl supernatants by
IFN-γ ELISA following the instructions of the manufacturer
(Thermo Fisher Scientific).
Enzymatic Activity of AEP
To determine the activity of AEP, cells were lysed by three cycles
of freezing and thawing. Subnuclear fractions were collected
by harvesting supernatants after centrifugation at 10,000 g for
20min. Protein concentrations were measured using the BCA
protein assay (Thermo Scientific). Cellular lysates (2 and 5 µg)
were resuspended in sodium citrate buffer (50mM, pH 5.5; 5mM
DTT, 0.1% CHAPS). Z-Ala-Ala-Asn-AMC (10µM; Bachem) was
added to the lysates for 30min at room temperature. Developing
fluorescence (excitation 370 nm; emission 460 nm) was measured
for 10min on a NOVOstar analyzer (BMG labtech).
Microarray Gene Analysis
Total RNAwas isolated using small- andmicro-scale RNAqueous
isolation kits (Ambion) and amplified using the TotalPrep RNA
amplification kit (Ambion). After preparation using the whole-
genome gene expression direct hybridization assay (Illumina),
cRNA samples were dispensed ontoHumanHT-12 v3 Expression
BeadChips (Illumina). Hybridization was performed in the
Illumina hybridization oven for 17 h at 58◦C. Microarray gene
expression data were analyzed using R 2.15. Normalization
was done in the lumi package, using the variance stabilizing
transformation and quantile normalization (30).
Statistical Analysis
Data were analyzed with Prism 8.3.0 (GraphPad Software Inc.).
If not otherwise stated, for statistical analysis, at least three
individual experiments were performed and the unpaired t-test
was applied. Statistical significance was indicated as ∗P < 0.05
or ∗∗P < 0.01. For WGAS, the level of matching between T-cell
recognition pattern and SNP data was calculated according to
Fisher’s exact test.
RESULTS
Identification of Four New HLA Class
II-Restricted Minor Histocompatibility
Antigens by WGAS
The target antigens of four CD4+ T-cell clones were identified
by WGAS. All T-cell clones have been shown to be specific for
minor histocompatibility antigens by recognizing patient but not
donor EBV-LCL. Clone 100 has been isolated from bone marrow
of patient 3,087, 5 weeks after donor lymphocyte infusion (DLI)
for relapsed chronic myeloid leukemia (CML) after alloSCT (9)
and was restricted to HLA-DRB1∗03:01. Clone 8-10A and clone
8-15 were isolated from peripheral blood of patient 2,877, 4 weeks
after DLI for relapsed CML after alloSCT andwere both restricted
to HLA-DQB1∗06:02. Finally, clone 15-18, which was also HLA-
DQB1∗06:02-restricted, was isolated from patient 5,852 who was
treated with DLI for mixed chimerism 6 months after alloSCT
for myelodysplastic syndrome refractory anemia with excess of
blasts type 2. To identify the target antigens of these T-cell clones,
we tested reactivity against a panel SNP-genotyped EBV-LCL
either transduced with HLA-DRB1∗03:01 (clone 100; Figure 1A)
or endogenously expressing HLA-DQB1∗06:02 (clones 8-10A, 8-
15, and 15-18) and correlated T-cell recognition data with SNP
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FIGURE 1 | Identification of LB-PIP4K2A-1S as new HLA class II-restricted minor histocompatibility antigen by whole genome association scanning. (A) T-cell
recognition of a panel of 80 HLA-DRB1*0301 transduced EBV-LCL. Bars represent the level of IFN-γ (ng/ml) in ELISA released by clone 100 upon co-incubation with
the different EBV-LCL. (B) Whole genome association scanning of the recognition data for 80 HLA-DRB1*0301 transduced EBV-LCL and the corresponding SNP
data revealed one strongly correlating missense SNP in PIP4K2A (rs10828317) (arrow). The y-axis indicates P-values for the significance of association between SNPs
and T-cell recognition of EBV-LCL. The x-axis represents the 1 million tested SNPs as distributed over the human chromosomes. (C) Synthetic peptides of patient and
donor variants were loaded on donor EBV-LCL in indicated concentrations and recognition by T-cell clone 100 was measured in IFN-γ ELISA. The
LB-PIP4K2A-1S-specific T-cell clone 100 also showed recognition of the donor PIP4K2A-1N variant at peptide concentrations over 50 nM.
genotypes of the respective EBV-LCL (27). The level of matching
was calculated according to Fisher’s exact test.
For clone 100, one SNP genotype significantly associated with
T-cell recognition with a P-value < 1 × 10−9 (Figure 1B). This
was a coding missense SNP (rs10828317) in PIP4K2A (HGNC
ID: 8997). Sequencing cDNA of patient and donor EBV-LCL for
the region encompassing the SNP confirmed heterozygosity in
patient cells at this position (G/A), whereas donor cells were
homozygous A/A. This A-to-G transition creates an Asn-to-
Ser substitution at amino acid position 251 (N->S251) of the
PIP4K2A protein.
For clone 8-10A, two SNPs (rs4242391 and rs1133782)
significantly associated with T-cell recognition with P-values <1
× 10−9. One of these SNPs (rs1133782) is a missense variant in
TNFRSF10D (HGNC ID: 11907). The T-to-C transition creates a
Leu-to-Ser substitution at amino acid position 310 (L->S310) of
the TNFRSF10D protein.
Two SNP genotypes (rs4740 and rs4905) with P-values <1 ×
10−8 associated with T-cell recognition by clone 8-15. Rs4740 is
a missense variant in EBI3 (HGNC ID: 3129) and the G-to-A
transition translates into a Val-to-Ile substitution at amino acid
position 201 (V->I201) of the EBI3 protein.
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Also for clone 15-18, two SNP (rs17700475 and rs6441226)
associated with T-cell recognition with P-values< 1× 10−9. SNP
rs6441226 is an intron variant in MFSD1 (HGNC ID: 25874),
which has a minor allele frequency (MAF) of 0.1478 in 1,000
Genomes. Searching the SNP database for a missense SNP with
a similar MAF revealed SNP rs28364680 that encodes a C-to-T
transition leading to a Pro-to-Ser substitution.
T-cell recognition of donor EBV-LCL loaded with
synthetic peptides surrounding the patient and donor
variants confirmed T-cell specificity for the patient variants
and validated these peptides as minor histocompatibility
antigens (Supplemental Table 1). T-cell clones 8-10A,
8-15, and 15-18 failed to recognize donor peptide
variants (Supplemental Figure 1). T-cell clone 100,
however, showed strong recognition of the donor variant
(INEGQKIYIDDNNKKVFLE) at peptide concentrations
>50 nM, while there was no recognition at lower peptide
concentrations (Figure 1C). The patient peptide variant
(INEGQKIYIDDNSKKVFLE) was recognized at peptide
concentrations>5 nM. These data indicate that the TCR of clone
100 is less able to discriminate between polymorphic peptides
than the TCR of clones 8-10A, 8-15, and 15-18, suggesting that
also other mechanisms are involved in differential recognition of
patient and donor EBV-LCL.
Surface Presentation of Donor Variant
PIP4K2A-1N Is Hampered by
AEP-Mediated Cleavage
To investigate whether donor EBV-LCL fail to present the
donor variant peptide as a consequence of low gene expression,
we established overexpression of PIP4K2A by retroviral
transduction. Interestingly, overexpression of full-length
PIP4K2A encoding donor variant PIP4K2A-1N induced only
low recognition of donor EBV-LCL, while significant recognition
was observed for transduced melanoma Mel-Juso (MJS) cells
(Figure 2). This suggests that another intracellular mechanism
than gene expression is involved in differential recognition of
LB-PIP4K2A-1S and its allelic variant. As the donor PIP4K2A-
1N variant is defined by an asparagine in substitution of a serine
in the patient variant, we hypothesized that the donor peptide
may be intracellularly cleaved by AEP (alias LGMN) as described
for other antigens (26). We therefore expressed the full-length
patient and donor genes for PIP4K2A in melanoma cell line
SD1, which expressed a tet-off system with AEP under control of
doxycycline (26). Testing T-cell recognition of these transduced
SD1 cell lines revealed increased recognition of PIP4K2A-1N
after treatment with doxycycline, which shuts down AEP
enzyme activity (Figure 3A). To confirm these data, we cloned
the AEP gene and retrovirally overexpressed the protein in
MJS cells co-transduced with the PIP4K2A variants. T-cell
recognition of PIP4K2A-1N was significantly decreased upon
overexpression of AEP, while recognition of LB-PIP4K2A-1S
was not affected (Figure 3B). These data indicated that donor
variant PIP4K2A-1N is enzymatically cleaved by AEP, thereby
hampering presentation and T-cell recognition of the epitope at
the cell surface.
Low Expression of AEP in Primary AML and
Healthy CD34+ Hematopoietic Stem Cells
We hypothesized that enzymatic cleavage of donor variant
PIP4K2A-1N could potentially be overcome by high expression
of the substrate, i.e., PIP4K2A, or low expression or
activity of AEP, and therefore analyzed mRNA expression
of PIP4K2A and AEP by microarray gene analysis (Figure 4 and
Supplemental Table 2). In addition to MJS and various other
cancer cell lines, we analyzed gene expression in a wide variety
of primary cell types of hematopoietic and non-hematopoietic
origin, including bone marrow and PBMC, primary T- and
B-cells, monocytes, macrophages, monocyte-derived immature
and mature dendritic cells, healthy CD34+ hematopoietic
stem cells, acute and chronic myeloid leukemia, acute and
chronic lymphocytic leukemia, and multiple myeloma as well as
FIGURE 2 | Cell type-specific recognition of endogenously expressed PIP4K2A-1N donor variant. Full-length genes encoding LB-PIP4K2A-1S and PIP4K2A-1N were
retrovirally transduced in MJS (left) or donor EBV-LCL (right) and transduced cells were isolated by flow cytometric sorting based on expression of marker gene GFP.
T-cell recognition by clone 100 of the different cell lines was measured in IFN-γ ELISA. Indicated is the release of IFN-γ (ng/ml) by T-cell clone 100 upon co-incubation
with indicated numbers of transduced MJS cells or EBV-LCL. Indicated are mean and standard deviation of duplicate wells. One representative of three independent
experiments is shown.
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FIGURE 3 | Recognition of endogenously expressed PIP4K2A-1N donor
variant correlates with activity of asparagine endopeptidase AEP. (A) SD1 cells
expressing a tet-off vector system with AEP were retrovirally transduced with
full-length genes encoding the LB-PIP4K2A-1S patient variant or PIP4K2A-1N
donor variant and tested for T-cell recognition with and without prior doxycyclin
(dox) treatment (left). Enzyme activity with and without doxycyclin treatment
has been measured in cellular lysates (right). NC, negative control. (B) T-cell
recognition of MJS retrovirally transduced with full-length genes encoding
LB-PIP4K2A-1S patient variant or PIP4K2A-1N donor variant with or without
additional transduction of AEP (LGMN). T-cell recognition has been tested in
IFN-γ ELISA (left). Enzyme activity of AEP has been measured in transduced
cell lines and fetal calf serum (FCS) as negative control (right). *P < 0.05; **P <
0.01 (unpaired t-test). One representative of three independent experiments
is shown.
primary fibroblasts, keratinocytes, proximal tubular epithelial
cells, human umbilical vein endothelial cells, melanocytes,
hepatocytes, and gut, lung, bile duct, and cornea epithelial cells.
Various non-hematopoietic cell types were also cultured in
the absence or presence of IFN-γ to mimic an inflammatory
environment. Interestingly, we observed low expression of AEP
especially in primary AML and CD34+ hematopoietic stem cells,
while PIP4K2A expression was less variable.
Primary AML Elicit T-Cell Reactivity
Independent of Their SNP Status
Since AEP expression is low in primary AML and CD34+
hematopoietic progenitor cells, we tested whether T-cell clone
100 could recognize PIP4K2A peptides on these cell types
independent of the patient SNP. Primary AML cells were sorted
on CD33 by flow cytometry and tested for recognition by T-
cell clone 100 in IFN-γ ELISA. Data showed that all AML
that were positive for the relevant restriction molecule HLA-
DRB1∗0301 were recognized by the T-cell clone independent
of their SNP status (Figure 5A). In contrast, AML cells that
lacked HLA-DRB1∗0301 were not recognized. We also tested
activity of AEP in these cells and confirmed low or absent
enzyme activity, which is in line with low mRNA expression
in these cells. In addition to AML cells, T-cell recognition
of primary CD34+ hematopoietic progenitors was tested. In
contrast to AML, donor variant PIP4K2A-1N was not recognized
on CD34+ cells, which is probably due to low HLA class II
expression or other accessory molecules in these cells since
exogenous peptide loading also induced only marginal T-cell
recognition of LB-PIP4K2A-1S. In contrast, a CMV derived
antigen peptide presented in HLA-A∗02:01 mediated strong T-
cell recognition (Figure 5B). In conclusion, the data showed that
T-cell clone 100 recognizes primary AML independent of their
SNP status, thereby confirming surface presentation of donor
variant PIP4K2A-1N in the absence of AEP.
DISCUSSION
T-cells directed against minor histocompatibility antigens are
well established to mediate strong immune responses both
against residual malignant cells and potentially against healthy
non-malignant cells of the patient. A further understanding of
these T-cell responses is crucial for eventually separating the
effects of GvL and Graft vs. host disease. We here present four
new HLA class II-restricted minor histocompatibility antigens
identified by WGAS. Furthermore, we demonstrate that one of
the new antigens is differentially presented on patient and donor
cells due to intracellular cleavage of the donor peptide by AEP.
This enzyme is not or less active in AML due to low expression
of the endopeptidase. As a result, AML cells can be targeted
by donor T-cells independent of the SNP status. These data
illustrate that endopeptidases can play a role in cell type-specific
intracellular processing and presentation of HLA class II antigens
and provide evidence that after alloSCT, donor T-cells for minor
histocompatibility antigens can also target the respective allelic
variants as cell type-specific autoantigens.
Although it has been shown for various HLA class I-restricted
minor histocompatibility antigens that their immunogenicity is
based on differential intracellular processing of patient and donor
variant peptides (21, 22, 24), all so far identified HLA class II-
restricted minor histocompatibility antigens are recognized by T-
cell receptors that fail to react with donor variants. Also, for three
new HLA class II antigens identified here, donor variants are
not recognized when loaded as exogenous peptides, indicating
that patient and donor peptides are differentially recognized
by the T-cell receptor as expressed by the specific T-cell clone.
Alternatively, it is also possible that the donor peptide does
not sufficiently bind to the HLA molecule and is therefore
not presented, as described for HA-1 (25). However, for one
new HLA class II antigen, i.e., LB-PIP4K2B-1S, we observed
that its donor variant PIP4K2A-1N is strongly recognized when
pulsed as exogenous peptide, suggesting involvement of an
intracellular processing mechanism in differential recognition
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FIGURE 4 | RNA expression of PIP4K2A and AEP in various human cell types by microarray gene analysis. (A) PIP4K2A gene expression in primary cells. (B) AEP
gene expression in primary cells. (C) PIP4K2A gene expression in cell lines. (D) AEP gene expression in cell lines. Healthy and malignant hematopoietic cells are
represented by gray and black dots, respectively, while open symbols represent non-hematopoietic cell types. Gene expression was measured on Illumina HT-12
BeadChips as described previously (30). BMMC, bone marrow mononuclear cells; PBMC, peripheral blood mononuclear cells; Mono, monocytes, Mø1, type 1
macrophages; Mø2, type 2 macrophages; imDC, immature dendritic cells; matDC, mature dendritic cells; HSC, hematopoietic CD34+ stem cells; EBV-B,
EBV-transformed B cells; PHA-T, PHA-stimulated T-cells; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MM,
multiple myeloma; FB, fibroblasts; KC, keratinocytes; PTEC, proximal tubular epithelial cells; HUVEC, human umbilical vein endothelial cells.
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FIGURE 5 | Primary human AML are recognized independent of the SNP for PIP4K2A. (A) Recognition of primary human AML by T-cell clone 100 as tested in IFN-γ
ELISA (top panel). PIP4K2A genotypes [N/N (light gray), S/N (dark gray), or S/S (black)] are depicted for HLA-DRB1*03 positive primary AML. EBV-LCL 3087 is
derived from the patient from whom T-cell clone 100 has been isolated, and EBV-LCL 3089 is from its stem cell donor. Enzyme activity of AEP has been measured in
corresponding AML cell lysates (bottom). n.d., not determined. (B) T-cell recognition of primary human CD34+ cells has been tested by IFN-γ ELISA (top panel).
PIP4K2A genotypes (N/N, S/N, or S/S) are depicted. Both patients are typed positive HLA-DRB1*03:01, patient JH is in addition typed positive for HLA-A*02:01 and
viability of CD34+ cells is confirmed by recognition of CMV peptide NLV in HLA-A*02:01. Enzyme activity of AEP in CD34 cell lysates is depicted (bottom). One
representative of two independent experiments is shown.
of patient and donor variant. Of note, peptide titration still
showed a marked difference in T-cell activation between LB-
PIP4K2A-1S and its donor variant, indicating that intracellular
processing is not the only mechanism and that the affinity of
the T-cell receptor as expressed by the specific T-cell clone
also contributes to differential recognition of patient and donor
peptides. However, the observation that AEP strongly affects
endogenous presentation of donor variant PIP4K2A-1N, but not
of LB-PIP4K2A-1S, confirmed involvement of this endopeptidase
in intracellular processing of the HLA class II antigen.
A role for AEP in antigen processing has already been
described for other antigens. For tetanus toxin C fragment
(TTCF), it has been demonstrated that deamidation of an
asparagine residue hinders enzymatic cleavage by AEP, thereby
perturbing antigen presentation (31). Whereas cleavage by AEP
enhances antigen presentation for TTCF, presentation of LB-
PIP4K2A-1S is disrupted. Similarly, it has been shown for myelin
basic protein (MBP), which is an autoantigen in the inflammatory
demyelinating disease multiple sclerosis, that autoreactive T-
cells can evade central tolerance due to enzymatic cleavage
of the autoantigen in the thymus (26). It has been suggested
that under certain circumstances, these MBP-specific T-cells
may become activated and induce autoimmunity. One of these
circumstances may be the posttranslational modification of the
asparagine residue by deamidation, thereby hindering cleavage
and enhancing MBP antigen presentation. Non-enzymatic
deamidation of asparagine to aspartic acid is the most commonly
observed posttranslational modification in proteins. Although
the C-terminally flanking lysine in PIP4K2A-1N is not ideal,
deamidation of the asparagine can occur at intermediate turnover
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rates (32) andmay therefore contribute to surface presentation of
the donor variant.
Apparently, in the stem cell donor for patient 3,087, a
T-cell expressing a TCR for donor variant PIP4K2A-1N has
evaded central tolerance, suggesting that the donor variant
is not expressed during thymic selection. This is in line
with our observation that even non-physiological levels of
overexpression of the donor variant does not lead to strong
T-cell activation. This, together with the observation that the
stem cell donor and the transplanted patient lack any signs of
autoimmunity, indicates that donor variant PIP4K2A-1N is not
or not sufficiently presented on all or the majority of healthy
tissues in vivo.
Thinking about therapeutic approaches, it is tempting to
speculate that the TCR as expressed by the T-cell clone for
LB-PIP4K2A-1S could be used for gene therapy to treat AML
in patients who are homozygous for the donor variant (N/N)
without need of prior transplantation. In this setting, the TCR
is expected to selectively recognize PIP4K2A-1N as tumor
antigen on low AEP-expressing leukemic cells, whereas all or
the majority of healthy tissues are not expected to present the
epitope due to intracellular AEP-mediated cleavage. While low
expression of AEP in healthy CD34+ hematopoietic stem cells
is of concern, our in vitro experiments failed to show any T-
cell recognition of these cells, probably due to a low overall
HLA class II expression or lack of other accessory molecules
stimulatory capacity in these cells. Moreover, we isolated the
T-cell clone for LB-PIP4K2A-1S during GvL reactivity from a
patient who was transplanted with CD34+ hematopoietic stem
cells from a PIP4K2A-1N homozygous donor, but had no signs
of myeloablation. However, it cannot entirely be excluded that
side effects may occur due to presentation of PIP4K2A-1N on
certain cell types or healthy tissues as a result of low AEP
expression or posttranslational modification of the asparagine
residue. Although it is tempting to speculate, we would like to
emphasize that we do not present PIP4K2A-1N as ideal target
for immunotherapy of AML, since that conclusion requires
additional in vitro and in vivo experiments, but rather as proof
of concept that endopeptidases play a similar role in cell type-
specific intracellular processing of HLA class II-restricted minor
histocompatibility antigens as intracellular processing is known
to be involved in presentation of HLA class I-restricted minor
histocompatibility antigens (21–23).
Another question is why AML cells express low amounts of
AEP and whether this can be influenced. Intriguingly, it was
recently described that AEP is downregulated by PD-1 signaling
in regulatory T-cells (33). It is tempting to speculate that this
may also occur in tumor cells during immune evasion (34).
This would make PIP4K2A-1N more attractive as a leukemia-
associated antigen to be targeted by immunotherapy perhaps
after or during treatment with cisplatin, a chemotherapeutic
agent that is known to induce deamidation (35). Altogether,
convincing evidence that PIP4K2A-1N can be used as a leukemia-
specific target is lacking and demands further exploration using
in vivo models. Nevertheless, discovery of LB-PIP4K2A-1S as
a new minor histocompatibility antigen revealed an interesting
role of an endopeptidase in cell type-specific intracellular
processing of this HLA class II-restricted antigen and its donor
variant, which may be explored in future immunotherapy
of AML.
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